Attention Deficit Hyperactivity Disorder
- Conditions
- Behavior DisordersAttention Deficit Hyperactivity DisorderBehavior Hyperactive
- Interventions
- Other: Patients suffering from the co-occurrence of ADHD and addiction(s)
- Registration Number
- NCT06232226
- Lead Sponsor
- Nantes University Hospital
- Brief Summary
The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.
- Detailed Description
Information on the study and diagnosis of ADHD will be carried out during a medical evaluation consultation, as part of routine care.
The two research visits (inclusion and at 12 months) will be added by the research and will each include:
* A structured clinical interview with a research professional (traceability of oral consent, administration of structured interviews, collection of self-questionnaires, collection of care from the medical record)
* A neuropsychological assessment with a neuropsychologist
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Neuropsychological assessment Patients suffering from the co-occurrence of ADHD and addiction(s) Determination of the neuropsychological profile
- Primary Outcome Measures
Name Time Method Functional impairment Inclusion and 12-month follow-up Weiss Functional Impairment Rating Scale (WFIRS-S) (scores of the 7 domains and total score)
- Secondary Outcome Measures
Name Time Method Type and severity of ADHD Inclusion Diagnostiscal Interview Voor Attention deficit hyperactivity disorder (DIVA-5)
Symptoms of ADHD Inclusion and 12-month follow-up Adult ADHD Self-Report Scale Symptom Checklist (ASRS-1.1) (inattention and hyperactivity/impulsivity scores)
Addictive disorders - substance use disorders (including tobacco, alcohol and other substances) Inclusion and 12-month follow-up Mini International Neuropsychiatric Interview- Simplified for Diagnostic and Statistical Manual (DSM)-5 (MINI-S)
Addictive disorders - gambling disorder Inclusion and 12-month follow-up Structured interview adapted from the NODS to explore the diagnostic criteria proposed in the third section of the DSM-5 for the Internet gaming disorder
Addictive disorders - sex addiction Inclusion and 12-month follow-up Structured interview adapted from the NODS to explore the diagnostic criteria proposed by Carnes et al in 2012
Addictive disorders - eating addiction Inclusion and 12-month follow-up Yale Food Addiction Scale (YFAS 2.0)
Psychiatric disorders Inclusion and 12-month follow-up MINI-S
Neuropsychological profile - selective attention Inclusion and 12-month follow-up D2-R test (CCT standard score, E% standard score and CC standard score)
Neuropsychological profile - short-term and working memory Inclusion and 12-month follow-up Digit memory test (standardized scores of numbers of items correctly recalled (direct order, indirect order, ascending order, total), span sizes (direct order, indirect order, ascending order))
Neuropsychological profile - inhibition Inclusion and 12-month follow-up Stroop test (standardized execution times (naming condition, interference condition), standardized numbers of uncorrected errors (naming condition, interference condition), and standardized interference score)
Neuropsychological profile - spontaneous flexibility Inclusion and 12-month follow-up Verbal fluency test (standardized scores for the number of words cited and the number of errors, in both conditions (literal and categorical))
Neuropsychological profile - planning Inclusion and 12-month follow-up Zoo test (total profile score)
Psychopathological profile - impulsivity Inclusion and 12-month follow-up Urgency, Premeditation (lack of), Perseverance (lack of), Sensation seeking impulsivity behavior scale (UPPS-P) (5 scores)
Psychopathological profile - emotional dysregulation Inclusion and 12-month follow-up Difficulties in Emotion Regulation Scale (DERS-16) (5 scores and total score)
Psychopathological profile - sensorial profile Inclusion and 12-month follow-up Sensory profile of Winnie Dunn - adult version (category and raw scores in the 4 quadrants)
Psychopathological profile - self-esteem Inclusion and 12-month follow-up Rosenberg Self-Esteem Scale (RSES) (total score)
Quality of life survey Inclusion and 12-month follow-up World Health Organization Quality Of Life (WHOQoL-26) (4 scores)
Care received 12-month follow-up Effective implementation of treatment with MPH (yes/no) or atomoxetine (yes/no), If no, reasons for not implementing it (for MPH), Care provided (Cognitive remediation / behavioral and cognitive therapy / psychoeducation / other psychosocial intervention (details) / other drug treatment), Reported compliance and misuse for MPH and atomoxetine, Reported compliance for non-drug care, Tolerance: numerical scale from 0 to 10 for the evaluation of the main adverse effects (for MPH and for atomoxetine).
Personal and family medical history Inclusion List of somatic, psychiatric and addictive disorders for personal history, list of psychiatric and addictive disorders for family history
Sociodemographics Inclusion Age, gender, level of education, professional status, number of children
Trial Locations
- Locations (3)
CHRU de Brest
🇫🇷Brest, France
CHRU de Tours
🇫🇷Tours, France
Nantes University Hospital
🇫🇷Nantes, Loire-Atlantique, France